OncoGenex Pharmaceuticals, Inc. — Q1 2013 Form 10-Q
Filing identity: The supplied filing is for OncoGenex Pharmaceuticals, Inc., not Achieve Life Sciences, Inc. It covers the quarter ended March 31, 2013; financial amounts below are in U.S. dollars.
Business context
OncoGenex was a clinical-stage biopharmaceutical company developing cancer therapies. It had no product-sales revenue; reported revenue came from its Teva collaboration, including reimbursement of development costs. Its principal programs were custirsen, OGX-427 and preclinical candidate OGX-225.
Financial performance and position
| Metric | Q1 2013 | Q1 2012 / prior date |
|---|---|---|
| Collaboration revenue | $5.1 million | $1.3 million |
| Research and development expense | $10.9 million | $5.1 million |
| General and administrative expense | $2.5 million | $1.7 million |
| Net loss | $6.7 million | $6.9 million |
| Basic and diluted loss per share | $0.46 | $0.67 |
| Cash used in operations | $10.7 million | $7.4 million |
| Cash, cash equivalents and short-term investments | $64.6 million | $75.4 million at Dec. 31, 2012 |
| Total assets | $75.4 million | $82.0 million at Dec. 31, 2012 |
| Total liabilities | $15.1 million | $15.8 million at Dec. 31, 2012 |
Collaboration revenue rose substantially, primarily with increased AFFINITY trial activity. R&D expense more than doubled, reflecting clinical-trial enrollment and related costs, partly offset by lower OGX-427 manufacturing expense. The net loss narrowed despite higher operating expenses, principally because the company recorded a $1.4 million noncash warrant revaluation gain, versus a $1.4 million loss in Q1 2012. Loss per share also benefited from a higher weighted-average share count.
Cash and investments declined by $10.8 million from year-end. Operating cash outflow was partly offset by $11.2 million of investing cash inflow, mainly investment maturities; financing provided only $10,000, versus $53.8 million in Q1 2012, when a public offering generated proceeds. Receivables included $5.1 million of unbilled Teva reimbursements, invoiced in April. Current assets were $73.5 million and current liabilities $11.0 million. Balance-sheet obligations totaled $5.2 million, including the excess-facility lease liability; the filing does not identify material conventional borrowing debt.
Material changes, outlook and risks
- Management said existing cash, investments and Teva receivables were expected to fund currently planned operations into 2015, and anticipated cash needs were covered for at least 12 months. This outlook depends on trial timing and costs, Teva’s performance, and the company’s development plans.
- Management expected R&D expense to increase, potentially significantly, as custirsen and OGX-427 development expanded. Teva was expected to reimburse $1.2 million to $2.0 million annually in FTE costs during 2013–2014. The company did not expect Teva milestone or royalty payments in 2013.
- Custirsen SYNERGY enrollment was complete; final results were projected for the first half of 2014, based on anticipated death events in Q4 2013. AFFINITY and ENSPIRIT Phase 3 trials were ongoing. Borealis-1 was expected to complete enrollment in the second half of 2013; additional OGX-427 trials and OGX-225 toxicology work were planned.
- The company had no assurance that clinical trials would succeed, meet timelines, or support regulatory approval. Key risks included reliance on Teva for custirsen development, trial enrollment and safety outcomes, third-party manufacturing and funding needs. Additional capital could be required if costs rose, plans expanded, or trials extended beyond the projected runway; financing might not be available on acceptable terms.
- Isis disputed the company’s interpretation of its share of potential Teva milestone payments. OncoGenex believed some sales-related milestones could be treated as royalty revenue and subject to a lower payment, but stated there was no assurance that this position would prevail or that payment would be below 30%.
- The company recorded a $4.4 million excess-facility lease liability and disclosed substantial remaining Bothell lease payments if space could not be exited or sublet. No material subsequent events were reported. Management assessed disclosure controls as effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the filing’s registrant: OncoGenex Pharmaceuticals, Inc., rather than Achieve Life Sciences, Inc.
- Check actual trial progress and results against management’s stated timelines, especially SYNERGY and the OGX-427 studies.
- Monitor cash burn, receivable collection from Teva, and whether the stated runway into 2015 remains achievable.
- Review the Teva collaboration’s continuation, reimbursement obligations, and the unresolved potential Isis milestone-payment exposure.
- Assess whether rising clinical costs, lease commitments, or delays create a need for additional financing and potential shareholder dilution.